Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
December 05 2016 - 7:30AM
PHILADELPHIA and OXFORD, United
Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics
plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer,
today announced that it has initiated a study of its NY-ESO
SPEAR(TM) T-cells in myxoid/round cell liposarcoma (MRCLS). Patient
screening is underway, and the results from this study in up to 15
patients will inform a potential future registration trial. The
initiation of screening in this study meets a milestone set forth
in the Company's strategic collaboration agreement with
GlaxoSmithKline plc (LSE/NYSE: GSK).
This is an open-label pilot study in
patients to assess preliminary safety and efficacy in this new
indication. Initially, 10 patients will be enrolled. If further
characterization of the treatment is required, up to 5 additional
patients may be enrolled. Eligible patients will be HLA-A*02:01,
HLA-A*02:05 and/or HLA-A*02:06 with advanced (metastatic or
inoperable) high grade MRCLS whose tumor shows positive NY-ESO-1
expression defined as greater than or equal to 30 percent of cells
that are 2+ or 3+ by immunohistochemistry. Patients will receive
preconditioning with fludarabine and cyclophosphamide at the same
dose that is being used in Cohort 4 of the Company's ongoing
synovial sarcoma study.
About MRCLS
Soft tissue sarcomas can develop from tissues like fat, muscle,
nerves, fibrous tissues, blood vessels, or deep skin tissues. There
are approximately 50 types of soft tissue sarcomas, including
MRCLS. Myxoid/round cell liposarcoma is associated with specific
chromosomal translocations and represents about 30 to 35 percent of
liposarcomas and 5 to 10 percent of all adult soft tissue sarcomas.
Myxoid/round cell liposarcoma commonly presents at an age ranging
from 35 to 55 years.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused
on novel cancer immunotherapy products based on its SPEAR (Specific
Peptide Enhanced Affinity Receptor) T-cell platform. Established in
2008, the Company aims to utilize the body's own machinery - the
T-cell - to target and destroy cancer cells by using engineered,
increased affinity TCRs as a means of strengthening natural patient
T-cell responses. Adaptimmune's lead program is a SPEAR T-cell
therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR
T-cell therapy has demonstrated signs of efficacy and tolerability
in Phase 1/2 trials in solid tumors and in hematologic cancer
types, including synovial sarcoma and multiple myeloma. Adaptimmune
has a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the
NY-ESO TCR program. In addition, Adaptimmune has a number of
proprietary programs. These include SPEAR T-cell therapies
targeting the MAGE-A10 and AFP cancer antigens, which both have
open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4
cancer antigen that is in pre-clinical phase with IND acceptance
targeted for 2017. The Company has identified over 25 intracellular
target peptides preferentially expressed in cancer cells and is
currently progressing 12 through unpartnered research programs.
Adaptimmune has over 250 employees and is located in Oxfordshire,
U.K. and Philadelphia, USA. For more
information: http://www.adaptimmune.com
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve certain risks and
uncertainties. Such risks and uncertainties could cause our actual
results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the
success, cost and timing of our product development activities and
clinical trials and our ability to successfully advance our TCR
therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties
that could cause our actual results to differ materially from those
expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission (SEC) on November 10, 2016, and our other SEC filings.
The forward-looking statements contained in this press release
speak only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements
to reflect subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts@adaptimmune.com
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Adaptimmune Therapeutics plc via
Globenewswire
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024